DAX23.685 +0,9%Est505.645 +1,3%MSCI World4.343 -0,1%Top 10 Crypto11,91 -2,4%Nas23.216 +0,8%Bitcoin75.037 -0,6%Euro1,1598 +0,2%Öl62,35 -0,5%Gold4.163 +0,8%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 NVIDIA 918422 DroneShield A2DMAA Alphabet A (ex Google) A14Y6F RENK RENK73 Novo Nordisk A3EU6F Bayer BAY001 Lufthansa 823212 Siemens Energy ENER6Y Deutsche Telekom 555750 Amazon 906866 TKMS thyssenkrupp Marine Systems TKMS00 BASF BASF11 Tesla A1CX3T HENSOLDT HAG000
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX fester -- Wall Street höher -- BioNTech übernimmt CureVac -- Infineon, Urban Outfitters, SAP, TKMS, HP, DroneShield, Alphabet, Rüstungsaktien, Novo Nordisk, BYD im Fokus
Top News
HP-Aktie schwach: Massiver Stellenabbau geplant - Quartalsgewinn sinkt HP-Aktie schwach: Massiver Stellenabbau geplant - Quartalsgewinn sinkt
Apple-Aktie höher: Samsung wird laut Analysen 2025 als Smartphone-Marktführer abgelöst Apple-Aktie höher: Samsung wird laut Analysen 2025 als Smartphone-Marktführer abgelöst
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Iovance Biotherapeutics Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
2,10 EUR -0,05 EUR -2,37 %
FSE
2,47 USD -0,01 USD -0,20 %
BTT
Iovance Biotherapeutics jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)
Smartphone

Marktkap.857,09 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2DT49

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS4622601007

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolIOVA

Iovance Biotherapeutics Aktien News

DatumMeistgelesen
MotleyFoolDown 75% in 12 Months, Can Iovance Biotherapeutics Stock Turn Things Around?
ZacksIovance Biotherapeutics (IOVA) Reports Q3 Loss, Lags Revenue Estimates
MotleyFoolBetter Beaten-Down Stock: Iovance Biotherapeutics vs. Teladoc Health
Wer­bungIovance Biotherapeutics-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
MotleyFoolIs Iovance Biotherapeutics Stock Your Ticket to Becoming a Millionaire?
MotleyFoolWhy Iovance Biotherapeutics Stock Got Mashed on Monday
MotleyFoolWhy Iovance Biotherapeutics Stock Was Climbing Today
MotleyFoolWhy Iovance Biotherapeutics Stock Plummeted Today
BenzingaWhat 7 Analyst Ratings Have To Say About Iovance Biotherapeutics
BenzingaIovance Biotherapeutics Declines 29% In Premarket Trading: Here's What's Happening
ZacksIovance Biotherapeutics (IOVA) Reports Q2 Loss, Lags Revenue Estimates
MotleyFoolIs Iovance Biotherapeutics Stock Due for a Big Rally?
PR NewswireLost Money on Iovance Biotherapeutics, Inc.(IOVA)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
PR NewswireIOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
PR NewswireIOVA Deadline: IOVA Investors with Losses in Excess of $100K Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - IOVA
PR NewswireIOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
PR NewswireIOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
MotleyFoolWhy Iovance Biotherapeutics Stock Dove by Almost 15% This Week
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA
PR NewswireIovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA
PR NewswireIOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
PR NewswireIOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV
PR NewswireIOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA
PR NewswireIOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
PR NewswireIOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit
PR NewswireIOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
MotleyFoolDown More Than 75% This Year, Should Investors Throw in the Towel on Iovance Biotherapeutics Stock?
PR NewswireINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA
PR NewswireIOVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Iovance Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
PR NewswireIOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit
MotleyFoolWhy Iovance Biotherapeutics Tumbled by Nearly 6% Today
MotleyFoolWhy Iovance Biotherapeutics Stock Is Crashing Today
BenzingaExpert Outlook: Iovance Biotherapeutics Through The Eyes Of 9 Analysts
ZacksIovance Biotherapeutics (IOVA) Reports Q1 Loss, Misses Revenue Estimates
MotleyFoolIovance Biotherapeutics Stock Is Crashing. And Here's Why Things Could Get Even Worse This Year.
MotleyFoolIs Iovance Biotherapeutics a Millionaire-Maker?

Iovance Biotherapeutics News

Iovance Biotherapeutics News: auf dieser Seite finden Sie alle Iovance Biotherapeutics News und Nachrichten zur Iovance Biotherapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Iovance Biotherapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Iovance Biotherapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.